Compare Natera Inc. Common Stock (NTRA) vs Workday Inc (WDAY) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

Workday (WDAY) trades at $186.02, down 1.18% on the day, reflecting a recent market pullback amid broader tech sector volatility. The stock maintains a bullish technical signal with strong analyst consensus support, evidenced by 50.6% buy ratings and a $203.19 average price target. Recent earnings beats and a 200% YoY surge in AI Annual Recurring Revenue to $600 million highlight robust fundamental momentum, though net cash flow turned negative in 2025 due to strategic investments.

WDAY's outlook remains positive, driven by AI integration and expansion into new markets like the UAE, but risks include execution challenges from recent layoffs and heightened competition. The stock's premium valuation (P/E 37.89) requires sustained high growth to justify further upside, making earnings performance the critical near-term catalyst.